Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipatasertib (Primary) ; Ipatasertib (Primary)
  • Indications Breast cancer; Endometrial cancer; Gastrointestinal cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech

Most Recent Events

  • 01 Dec 2021 Results assessing single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects published in the Cancer Chemotherapy and Pharmacology
  • 01 Dec 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
  • 02 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top